Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of ularitide in acute decompensated heart failure
2006-002403-13Phase 3Terminated
- Sponsor
- PDL BioPharma
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and Acute Heart Failure (AHF) comparing Ularitide with Placebo (2 arms). Primary endpoints: Dyspnea improvement at 6 hours, Subject global assessment improvement at 6 hours and 2 more. Started Sep 2006; status: terminated.
02
Drugs
ularitide
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2006-002403-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002403-13.